Latest from UCSF Helen Diller Family Comprehensive Cancer Center

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco (UCSF), discusses the future of imaging for biochemical recurrent prostate cancer.
Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).
Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.
Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.
Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.
Michelle E. Melisko, MD, discusses a variety of pivotal trials with adjuvant hormonal therapy and other developments in the treatment of patients with ER-positive breast cancer.
Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.
Laura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.
Publication Bottom Border
Border Publication
x